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Introduction: Sunflower (Heliantus annuus L.) widely known as
medicinal plant for treating several diseases, such as
hypertension, allergy, pain, inflammation, and cancer. It contains
various bioactive compounds which some of them were
hellianuols. Hellianuols are a sesquiterpene lactones which
marked by benzene fused 6- to 8-membered cyclic ether ring
structure. To make sure that hellianuols were adequate for
development as a new chemical entities, we predicted some
pharmacokinetic parameters of several hellianuols compounds (A
to L) through in silico approach. Methods: We constructed 3
dimensional structures of hellianuol A, B, C, D, E, F, G, H, I, J, K
and L then generated the SMILE codes of each compound. These
codes then used as main material for running pkCSM online tool
to predict absorption, distribution, metabolism, and excretion
profile of each compounds. Results: Helianuols predicted to be
well absorbed in intestine (90.793% to 95.384% permeability),
skin (Log Kp: -2.662 to -3.570), and high permeability against
monolayer Caco-2 cell lines (LogPapp: 1.186 to 1.341 ×10-6cm/s).
Unfortunately, it had been predicted that hellianuols poorly
distributed in the body based on volume of distribution at steady
state (VDSS: 0.094 to 0.317) value. But its also predicted that most
of hellianuols had a capability to pass through blood-brain
barriers (LogBBB: up to 0.389) and penetrated into central
nervous system as well. Only hellianuol G, H and K predicted to
be metabolized by CYP1A2 inhibitor and only hellianuol A, B, D,
E and K metabolized by CYP2C19. Also predicted that hellianuols
were excreted in around 0.719 to 1.082 mg/kg/day. Conclusion:
Hellianuols contained in leaf aqueous extract of sunflower
predicted to be a good new pharmaceutical entities candidate
based on its pharmacokinetic profiles.
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INTRODUCTION
The discovery of new chemical
entities originated from plants has
attracted much attention in the last two
decades. It is becoming more important to
implement modern methodologies and
innovative strategy for designing an
effective, safe, and acceptable new drug
(1). Qualified drug must meet some
standards of pharmacokinetics aspects,
abbreviated with ADME (Absorption,
Distribution, Metabolism, Excretion). It
takes more time and also costs for
conducting in vivo and in vitro data to
assure that drug candidates are good in
absorption, distribution, metabolism, and
excretion. Predicting pharmacokinetic
aspects through in silico and
computational modelling is important
nowadays, especially to cut off time and
cost requirement of a new drug discovery
(2).
Macias et al. were succesfully
isolated and elucidated 12 kinds of
sesquiterpene compounds from aqueous
extract of Helianthus annuus L. cv. SH-
222 leaves, namely: Hellianuol A, B, C,
D, E, F, G, H, I, J, K, and L (3,4).
Hellianuols structure marked with the
presence of benzenefused 6- to 8-
membered cyclic ether ring so they are
included in sesquiterpene compounds (5).
Some hellianuol (B, G, H) have a
benzoxepine ring inside their structure.
The structure of hellianuols A-L
represented in Figure 1. According to
Kuntala et al., derivatives of benzoxepine
showed various pharmacological effects
such as: antibacterial and anticancer
activity, anti-hypertension agent, estrogen
receptor modulator and anti-HIV agent
(6–10). Hellianuols itself widely observed
as natural herbicide agents due to its
herbicidal activities against wide range of
monocotyledons and dicotyledons (11).
MATERIALS AND METHODS
The structure of twelve hellianuols
were designed using ChemBio2D Draw
Ultra v12.0 (CambridgeSoft) and obtained
the SMILE string of each compound.
Using the SMILE string, we predicted
absorption, distribution, metabolism and
excretion (ADME) profiles of hellianuol
A-L. The prediction of twelve compounds
was conducted using pkCSM online tool
(http://biosig.unimelb.edu.au/pkcsm/predi
ction).
RESULTS AND DISCUSSION
The pharmacokinetic properties of
hellianuol A-L according to pkCSM
online tool are presented in Table 1.
Absorption
Hellianuol A-L exhibited high value
(90.763% to 95.384%) of predicted %
human intestinal absorption as their
values are above 80% (12). Hellianuol A-
L predicted to be skin permeable as their
skin permeability constant values (−2.662
to −3.570 logKp) are below -2.5 (13). The
ability of hellianuols to transport through
intestinal mucosa membrane were
predicted by apparent permeabilites of
Caco-2 cell line parameter (Papp) (14).
According to US FDA, Papp values
<1×10-6cm/s indicate poor permeability
and Papp >10×10-6cm/s indicate high
permeability, then hellianuol A-L
exhibited 1.186 to 1.341 ×10-6cm/s
LogPapp (15), it could be predicted that
hellianuol A-L were poorly permeable
through Caco-2 cell line. Another aspect
of absorption were predicted through
heliannuols interactions to P-glycoprotein
(P-gp), a transporter protein that play
several important roles during drug
absorption, especially for expelling
molecules out of cells (16). Based on their
structures, there are eight hellianuols (A,
B, C, D, E, G, H, L) predicted to be the
substrate of P-gp, thus only hellianuol F, I,
J and K could be absorbed without
extracted out of cells.
Distribution
Steady state volume of distribution
(Vdss) is a pharmacokinetic parameter to
estimate drug distribution within tissues.
The higher the Vdss value, the more drug
concentration is distributed into the tissue
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Figure 1. Chemical structures and common names of the 12 hellianuol compounds investigated in this
study.
than plasma (17). Vdss considered low if
its logarithmic form under -0.15 (logVdss
< -0.15) and high if above 0.45 (logVdss >
0.45) (18). Hellianuols showed
moderately distributed with logVdss
values range between 0.094 – 0.317.
Based on pkCSM result, LogBB
values of hellianuols vary between -0.616
and 0.389. Hellianuol A, B, D, G, H, and
K have such chemical structures that
allows them to readily cross the blood-
brain barrier (LogBB > 0.3), while
hellianuol C, E, F, I, J, and K predicted as
moderately distributed to the brain
(LogBB < 0.3) (18). It is also predicted
that hellianuol A, B, C, and D would
shows such good in situ brain perfusions
result (logPS > -2), while only hellianuol
L showed low prediction value (LogPS= -
3.189).
PkCSM could predict how molecules
are distributed within the body based on
their structure. From the data
supplemented in Table 1, we predicted
Hellianuol A Hellianuol B Hellianuol C
Hellianuol D Hellianuol E Hellianuol F
Hellianuol G Hellianuol H Hellianuol I
Hellianuol J Hellianuol K Hellianuol L
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that helainnuols could be well distributed
in the body. It could be assumed as well
that some hellianuols would be distributed
to the brain. Especially hellianuol A, B,
and D which have high values of LogBB
and LogPS, so they are predicted to
readily cross the blood-brain barrier and
penetrated directly into the central
nervous system (19,20).
Metabolism
Cytochrome P450s is an important
enzyme for xenobiotics metabolism in
liver. Two main subtype of cytochrome
P450 are CYP2D6 and CYP3A4.
Metabolism of hellianuols are predicted
based on models for different CYP
isoforms (CYP2D6, CYP3A4, CYP1A2,
CYP2C19, CYP2C9, CYP2D6, and
CYP3A4) (18,21). The results showed
that hellianuol G and H were predicted to
be CYP1A2 inhibitor, and hellianuol A,
B, D, and E were predicted to be
CYP2C19 inhibitor. This suggested that
hellianuols may not metabolised directly
in liver as they were not being the
substrate of Cytochrome P450 enzymes
family, but hellianuol A, B, D, E, G, H, K
may affect another drug metabolisms, as
they were predicted could be the
Cytochrome P450 inhibitor.
Excretion
Excretion profile of hellianuols were
predicted using drug total clearance
parameter (CLtot). Total clearance is a
combination of hepatic and renal
clearance, measured in log ml/min/kg (22).
The prediction results show that the total
clearance of hellianuol C is the highest
followed by hellianuol E, B, D, K, A, G,
H, F, L, I and J. Indicating that
bioavailability of hellianuol J is the
highest. The results also suggested that
hellianuols may not be the substrates of
Organic Cation transporter 2 (OCT2), a
renal uptake transporter that plays an
important role in drug elimination through
kidney. From the result above, we can
considerate that hellianuols excreted
through kidney in another mechanism
besides OCT2.
CONCLUSION
Based on in silico pharmacokinetic
profiles study of hellianuol A-L contained
in aqueous extract of Helianthus annuus L.
cv. SH-222 leaves using pkCSM online
tool, it can be concluded that overall
could be well absorbed through oral
administration. Hellianuols were quite
promising to be developed as a an
anticancer drug especially for brain
cancer, as they were predicted to be able
to penetrated blood-brain barrier into
central nervous system. Their properties
exhibited such a good pharmacokinetics
as well.
This study widely opens
opportunities for further research on
hellianuols, especially to produce more
accurate result prospectively in in vitro
and in vivo studies.
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Table 1. Predicted ADME properties of hellianuols
Properties
Hellianuol
A B C D E F G H I J K L
Empirical
formula
C14H20O3 C15H20O3 C16H22O3 C15H22O3 C16H22O3 C15H20O4 C15H20O3 C15H20O3 C15H20O4 C15H20O4 C15H20O3 C15H22O4
Molecular
weight (g/mol) 236.31 248.32 262.34 250.33 262.34 264.32 248.32 248.32 264.32 264.32 248.32 266.33
Absorption
Intestinal
absorption (%
absorbed)
90,793 91,239 91,473 90,763 91,369 94,255 93,800 93,800 92,542 92,542 93,593 95,384
Skin
permeability
(log Kp)
-3.21 -3,218 -3,241 -3,186 -3,215 -3,570 -2,942 -2,942 -3,314 -3,314 -2,662 -3,109
Caco-2
permeability
(log Papp in 10-6
cm/s)
1.297 1,283 1,252 1,295 1,295 1,248 1,287 1,287 1,186 1,186 1,341 1,206
P-glycoprotein
substrate
Yes Yes Yes Yes Yes No Yes Yes No No No Yes
P-glycoprotein
I inhibitor
No No No No No No No No No No No No
P-glycoprotein
II inhibitor
No No No No No No No No No No No No
Distribution
Vdss (log L/kg) 0.094 0,150 0,076 0,159 0,172 0,096 0,317 0,317 0,270 0,270 0,193 0,115
BBB
permeability
(logBB)
0.341 0,311 0,296 0,313 0,021 0,092 0,389 0,389 0,112 0,112 0,378 -0,616
Metabolism
CYP2D6
substrate
No No No No No No No No No No No No
CYP3A4
substrate
No No No No No No No No No No No No
CYP1A2
inhibitor
No No No No No No Yes Yes No No Yes No
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CYP2C19
inhibitor
Yes Yes No Yes Yes No No No No No Yes No
Properties Hellianuol
A B C D E F G H I J K L
CYP2D6
inhibitor
No No No No No No No No No No No No
CYP3A4
inhibitor
No No No No No No No No No No No No
Excretion
Total clearance
(log ml/min/kg) 0,947 1,011 1,082 0,948 1,078 0,895 0,905 0,905 0,719 0,719 0,974 0,824
Renal OCT2
substrate
No No No No No No No No No No No No
ADME, absorption, distribution, metabolism, excretion; Papp, apparent permeability coefficient; Kp, skin permeability constant; Vdss, volume of distribution at
steady state; BBB, blood-brain barrier; BB, blood-brain; CNS, central nervous system; PS, permeability-surface area; OCT2, organic cation transporter-2
